Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence

March 28th 2024

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

TTFields Meets Time to Intracranial Progression End Point in NSCLC Brain Metastases

March 27th 2024

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

First-Line Osimertinib Plus Chemo Demonstrates Consistent Benefit in EGFR-Mutant NSCLC

March 26th 2024

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

March 25th 2024

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC

March 25th 2024

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

March 22nd 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab

March 22nd 2024

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

First-Line Pembrolizumab Plus Olaparib Maintenance Misses Survival End Points in Metastatic Nonsquamous NSCLC

March 21st 2024

Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.

Becotarug Plus Osimertinib Elicits Responses in EGFR Exon 20 Insertion+ NSCLC

March 21st 2024

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.

Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC

March 20th 2024

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

Exploratory Analysis Shows Perioperative Nivolumab Confers Benefit in Resectable NSCLC, Irrespective of Neoadjuvant Treatment Cycles

March 20th 2024

Perioperative nivolumab improved responses in resectable non–small cell lung cancer, irrespective of the number of neoadjuvant treatment cycles completed.

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

March 16th 2024

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

Dr Zaha on the Risk of Cardiovascular Toxicity in Patients With Lung Cancer

March 15th 2024

Vlad Gabriel Zaha, MD, PhD, discusses the risk of cardiovascular toxicity in patients with lung cancer undergoing treatment with radiation.

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD

March 15th 2024

State of the Science Summit - Breast and Lung Cancer: Chaired by Anne Favret, MD, and Samantha DiBenedetto, MD.

Dr Singh on the Utility of Radiation Therapy in Lung Cancer

March 14th 2024

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Brown Details the Evolving Role of PCI and HA-PCI in Small Cell Lung Cancer

March 14th 2024

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

Study Reveals New Insights Into Immune System Role in Lung Cancer Risk

March 14th 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

Dr Pellini on the Clinical Utility of ctDNA Assays in NSCLC

March 13th 2024

Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.

Perioperative Tislelizumab Shows Marked Benefit in Both Squamous and Nonsquamous Resectable NSCLC

March 13th 2024

Federico Cappuzzo, MD, discusses the clinical significance of the RATIONALE-315 trial of perioperative tislelizumab in non–small cell lung cancer.